A citation-based method for searching scientific literature

Paolo F Caimi, Weiyun Ai, Juan Pablo Alderuccio, Kirit M Ardeshna, Mehdi Hamadani, Brian Hess, Brad S Kahl, John Radford, Melhem Solh, Anastasios Stathis, Pier Luigi Zinzani, Karin Havenith, Jay Feingold, Shui He, Yajuan Qin, David Ungar, Xiaoyan Zhang, Carmelo Carlo-Stella. Lancet Oncol 2021
Times Cited: 63







List of co-cited articles
505 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.
Gilles Salles, Johannes Duell, Eva González Barca, Olivier Tournilhac, Wojciech Jurczak, Anna Marina Liberati, Zsolt Nagy, Aleš Obr, Gianluca Gaidano, Marc André,[...]. Lancet Oncol 2020
158
66

Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Laurie H Sehn, Alex F Herrera, Christopher R Flowers, Manali K Kamdar, Andrew McMillan, Mark Hertzberg, Sarit Assouline, Tae Min Kim, Won Seog Kim, Muhit Ozcan,[...]. J Clin Oncol 2020
248
61

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Stephen J Schuster, Michael R Bishop, Constantine S Tam, Edmund K Waller, Peter Borchmann, Joseph P McGuirk, Ulrich Jäger, Samantha Jaglowski, Charalambos Andreadis, Jason R Westin,[...]. N Engl J Med 2019
50

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Jeremy S Abramson, M Lia Palomba, Leo I Gordon, Matthew A Lunning, Michael Wang, Jon Arnason, Amitkumar Mehta, Enkhtsetseg Purev, David G Maloney, Charalambos Andreadis,[...]. Lancet 2020
452
49

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.
Sattva S Neelapu, Frederick L Locke, Nancy L Bartlett, Lazaros J Lekakis, David B Miklos, Caron A Jacobson, Ira Braunschweig, Olalekan O Oluwole, Tanya Siddiqi, Yi Lin,[...]. N Engl J Med 2017
44

Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.
Michael Crump, Sattva S Neelapu, Umar Farooq, Eric Van Den Neste, John Kuruvilla, Jason Westin, Brian K Link, Annette Hay, James R Cerhan, Liting Zhu,[...]. Blood 2017
664
44

Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial.
Nagesh Kalakonda, Marie Maerevoet, Federica Cavallo, George Follows, Andre Goy, Joost S P Vermaat, Olivier Casasnovas, Nada Hamad, Josée M Zijlstra, Sameer Bakhshi,[...]. Lancet Haematol 2020
106
42

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.
Frederick L Locke, Armin Ghobadi, Caron A Jacobson, David B Miklos, Lazaros J Lekakis, Olalekan O Oluwole, Yi Lin, Ira Braunschweig, Brian T Hill, John M Timmerman,[...]. Lancet Oncol 2019
846
33

Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial.
Martin Hutchings, Franck Morschhauser, Gloria Iacoboni, Carmelo Carlo-Stella, Fritz C Offner, Anna Sureda, Gilles Salles, Joaquín Martínez-Lopez, Michael Crump, Denise N Thomas,[...]. J Clin Oncol 2021
73
30

Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
Christian Gisselbrecht, Bertram Glass, Nicolas Mounier, Devinder Singh Gill, David C Linch, Marek Trneny, Andre Bosly, Nicolas Ketterer, Ofer Shpilberg, Hans Hagberg,[...]. J Clin Oncol 2010
989
28

Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma.
Mehdi Hamadani, John Radford, Carmelo Carlo-Stella, Paolo F Caimi, Erin Reid, Owen A O'Connor, Jay M Feingold, Kirit M Ardeshna, William Townsend, Melhem Solh,[...]. Blood 2021
46
36

ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies.
Francesca Zammarchi, Simon Corbett, Lauren Adams, Peter C Tyrer, Konstantinos Kiakos, Narinder Janghra, Teresa Marafioti, Charles E Britten, Carin E G Havenith, Simon Chivers,[...]. Blood 2018
63
26

Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS).
Franck Morschhauser, Ian W Flinn, Ranjana Advani, Laurie H Sehn, Catherine Diefenbach, Kathryn Kolibaba, Oliver W Press, Gilles Salles, Hervé Tilly, Andy I Chen,[...]. Lancet Haematol 2019
114
23

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Bertrand Coiffier, Eric Lepage, Josette Briere, Raoul Herbrecht, Hervé Tilly, Reda Bouabdallah, Pierre Morel, Eric Van Den Neste, Gilles Salles, Philippe Gaulard,[...]. N Engl J Med 2002
20

CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy.
Bicky Thapa, Paolo F Caimi, Kirit M Ardeshna, Melhem Solh, Carmelo Carlo-Stella, Brad S Kahl, Mehdi Hamadani. Blood Adv 2020
25
48

Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
Maria Corinna A Palanca-Wessels, Myron Czuczman, Gilles Salles, Sarit Assouline, Laurie H Sehn, Ian Flinn, Manish R Patel, Randeep Sangha, Anton Hagenbeek, Ranjana Advani,[...]. Lancet Oncol 2015
174
19

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.
Bertrand Coiffier, Catherine Thieblemont, Eric Van Den Neste, Gérard Lepeu, Isabelle Plantier, Sylvie Castaigne, Sophie Lefort, Gérald Marit, Margaret Macro, Catherine Sebban,[...]. Blood 2010
905
19

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
T Philip, C Guglielmi, A Hagenbeek, R Somers, H Van der Lelie, D Bron, P Sonneveld, C Gisselbrecht, J Y Cahn, J L Harousseau. N Engl J Med 1995
17

Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.
Loretta J Nastoupil, Michael D Jain, Lei Feng, Jay Y Spiegel, Armin Ghobadi, Yi Lin, Saurabh Dahiya, Matthew Lunning, Lazaros Lekakis, Patrick Reagan,[...]. J Clin Oncol 2020
210
17

Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.
Johannes Duell, Kami J Maddocks, Eva González-Barca, Wojciech Jurczak, Anna Marina Liberati, Sven De Vos, Zsolt Nagy, Aleš Obr, Gianluca Gaidano, Pau Abrisqueta,[...]. Haematologica 2021
20
55

Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study.
Martin Hutchings, Rogier Mous, Michael Roost Clausen, Peter Johnson, Kim M Linton, Martine E D Chamuleau, David John Lewis, Anna Sureda Balari, David Cunningham, Roberto S Oliveri,[...]. Lancet 2021
28
39

Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.
Bruce D Cheson, Richard I Fisher, Sally F Barrington, Franco Cavalli, Lawrence H Schwartz, Emanuele Zucca, T Andrew Lister. J Clin Oncol 2014
15

Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.
W Jurczak, P L Zinzani, G Gaidano, A Goy, M Provencio, Z Nagy, T Robak, K Maddocks, C Buske, S Ambarkhane,[...]. Ann Oncol 2018
72
15

Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma.
Andreas Viardot, Marie-Elisabeth Goebeler, Georg Hess, Svenja Neumann, Michael Pfreundschuh, Nicole Adrian, Florian Zettl, Martin Libicher, Cyrus Sayehli, Julia Stieglmaier,[...]. Blood 2016
207
14

Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study.
E Van Den Neste, N Schmitz, N Mounier, D Gill, D Linch, M Trneny, N Milpied, J Radford, N Ketterer, O Shpilberg,[...]. Bone Marrow Transplant 2016
155
14

A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma.
Brad S Kahl, Mehdi Hamadani, John Radford, Carmelo Carlo-Stella, Paolo Caimi, Erin Reid, Jay M Feingold, Kirit M Ardeshna, Melhem Solh, Leonard T Heffner,[...]. Clin Cancer Res 2019
41
21

Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes.
Bjoern Chapuy, Chip Stewart, Andrew J Dunford, Jaegil Kim, Atanas Kamburov, Robert A Redd, Mike S Lawrence, Margaretha G M Roemer, Amy J Li, Marita Ziepert,[...]. Nat Med 2018
669
14

Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression.
Eric D Jacobsen, Jeff P Sharman, Yasuhiro Oki, Ranjana H Advani, Jane N Winter, Celeste M Bello, Gary Spitzer, Maria Corinna Palanca-Wessels, Dana A Kennedy, Pamela Levine,[...]. Blood 2015
181
14

Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12.
Michael Crump, John Kuruvilla, Stephen Couban, David A MacDonald, Vishal Kukreti, C Tom Kouroukis, Morel Rubinger, Rena Buckstein, Kevin R Imrie, Massimo Federico,[...]. J Clin Oncol 2014
243
14

CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma.
Ranjana Advani, Ian Flinn, Leslie Popplewell, Andres Forero, Nancy L Bartlett, Nilanjan Ghosh, Justin Kline, Mark Roschewski, Ann LaCasce, Graham P Collins,[...]. N Engl J Med 2018
474
14

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.
Frederick L Locke, David B Miklos, Caron A Jacobson, Miguel-Angel Perales, Marie-José Kersten, Olalekan O Oluwole, Armin Ghobadi, Aaron P Rapoport, Joseph McGuirk, John M Pagel,[...]. N Engl J Med 2022
47
19

Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study.
Maria-Elisabeth Goebeler, Stefan Knop, Andreas Viardot, Peter Kufer, Max S Topp, Hermann Einsele, Richard Noppeney, Georg Hess, Stefan Kallert, Andreas Mackensen,[...]. J Clin Oncol 2016
258
12

Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma.
David Dornan, Fiona Bennett, Yvonne Chen, Mark Dennis, Dan Eaton, Kristi Elkins, Dorothy French, Mary Ann T Go, Andrew Jack, Jagath R Junutula,[...]. Blood 2009
138
12

Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma.
Michael R Bishop, Michael Dickinson, Duncan Purtill, Pere Barba, Armando Santoro, Nada Hamad, Koji Kato, Anna Sureda, Richard Greil, Catherine Thieblemont,[...]. N Engl J Med 2022
28
28

Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.
Hagop M Kantarjian, Daniel J DeAngelo, Matthias Stelljes, Giovanni Martinelli, Michaela Liedtke, Wendy Stock, Nicola Gökbuget, Susan O'Brien, Kongming Wang, Tao Wang,[...]. N Engl J Med 2016
691
11

Is autologous transplant in relapsed DLBCL patients achieving only a PET+ PR appropriate in the CAR T-cell era?
Nirav N Shah, Kwang W Ahn, Carlos Litovich, Yizeng He, Craig Sauter, Timothy S Fenske, Mehdi Hamadani. Blood 2021
20
35

Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.
Wyndham H Wilson, Ryan M Young, Roland Schmitz, Yandan Yang, Stefania Pittaluga, George Wright, Chih-Jian Lih, P Mickey Williams, Arthur L Shaffer, John Gerecitano,[...]. Nat Med 2015
680
11

A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications.
George W Wright, Da Wei Huang, James D Phelan, Zana A Coulibaly, Sandrine Roulland, Ryan M Young, James Q Wang, Roland Schmitz, Ryan D Morin, Jeffrey Tang,[...]. Cancer Cell 2020
214
11

Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy.
Jay Y Spiegel, Saurabh Dahiya, Michael D Jain, John Tamaresis, Loretta J Nastoupil, Miriam T Jacobs, Armin Ghobadi, Yi Lin, Matthew Lunning, Lazaros Lekakis,[...]. Blood 2021
28
25

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.
A A Alizadeh, M B Eisen, R E Davis, C Ma, I S Lossos, A Rosenwald, J C Boldrick, H Sabet, T Tran, X Yu,[...]. Nature 2000
11

Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.
Roland Schmitz, George W Wright, Da Wei Huang, Calvin A Johnson, James D Phelan, James Q Wang, Sandrine Roulland, Monica Kasbekar, Ryan M Young, Arthur L Shaffer,[...]. N Engl J Med 2018
778
11

Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.
Matthew S Davids, Andrew W Roberts, John F Seymour, John M Pagel, Brad S Kahl, William G Wierda, Soham Puvvada, Thomas J Kipps, Mary Ann Anderson, Ahmed Hamed Salem,[...]. J Clin Oncol 2017
430
11

Diffuse Large B-Cell Lymphoma.
Laurie H Sehn, Gilles Salles. N Engl J Med 2021
82
11

Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity.
Caron A Jacobson, Bradley D Hunter, Robert Redd, Scott J Rodig, Pei-Hsuan Chen, Kyle Wright, Mikel Lipschitz, Jerome Ritz, Yusuke Kamihara, Philippe Armand,[...]. J Clin Oncol 2020
94
11

Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma.
John G Gribben, Nathan Fowler, Franck Morschhauser. J Clin Oncol 2015
171
11

Open-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
Luke Coyle, Nicholas J Morley, Alessandro Rambaldi, Kylie D Mason, Gregor Verhoef, Caroline L Furness, Alicia Zhang, A Scott Jung, David Cohan, Janet L Franklin. Leuk Lymphoma 2020
38
18

Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial.
Nicolas Mounier, Taoufik El Gnaoui, Hervé Tilly, Danièle Canioni, Catherine Sebban, René-Olivier Casasnovas, Richard Delarue, Anne Sonet, Pauline Beaussart, Tony Petrella,[...]. Haematologica 2013
96
11

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.
Michael Wang, Javier Munoz, Andre Goy, Frederick L Locke, Caron A Jacobson, Brian T Hill, John M Timmerman, Houston Holmes, Samantha Jaglowski, Ian W Flinn,[...]. N Engl J Med 2020
489
11

The 2016 revision of the World Health Organization classification of lymphoid neoplasms.
Steven H Swerdlow, Elias Campo, Stefano A Pileri, Nancy Lee Harris, Harald Stein, Reiner Siebert, Ranjana Advani, Michele Ghielmini, Gilles A Salles, Andrew D Zelenetz,[...]. Blood 2016
11

Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.
Hervé Tilly, Franck Morschhauser, Laurie H Sehn, Jonathan W Friedberg, Marek Trněný, Jeff P Sharman, Charles Herbaux, John M Burke, Matthew Matasar, Shinya Rai,[...]. N Engl J Med 2022
17
41


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.